Contineum Therapeutics, Inc.
CTNM
$14.19
-$1.11-7.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.33% | 12.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.10% | -1.23% | |||
| Operating Income | -3.10% | 1.23% | |||
| Income Before Tax | -4.83% | 4.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.83% | 4.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.83% | 4.62% | |||
| EBIT | -3.10% | 1.23% | |||
| EBITDA | -2.81% | 1.23% | |||
| EPS Basic | -4.47% | 21.16% | |||
| Normalized Basic EPS | -4.46% | 21.15% | |||
| EPS Diluted | -4.47% | 21.16% | |||
| Normalized Diluted EPS | -4.46% | 21.15% | |||
| Average Basic Shares Outstanding | 0.34% | 20.98% | |||
| Average Diluted Shares Outstanding | 0.34% | 20.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||